Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features

被引：9

作者：

Herrera Juarez, Mercedes ^{[1
]}

Tolosa Ortega, Pablo ^{[1
]}

Sanchez de Torre, Ana ^{[1
]}

Ciruelos Gil, Eva ^{[1
]}

机构：

[1] Univ Hosp 12 Octubre, Breast Canc Unit, Div Gynecooncol, Madrid, Spain

来源：

BREAST CARE | 2020年 / 15卷 / 03期

关键词：

Triple-negative breast cancer; Intrinsic subtypes; Biomarkers; Immuno-oncology; TUMOR-INFILTRATING LYMPHOCYTES; NEOADJUVANT CHEMOTHERAPY; ANDROGEN RECEPTOR; PROGNOSTIC VALUE; PHASE-II; ADJUVANT CAPECITABINE; PREDICTIVE-VALUE; GENE SIGNATURE; EXPRESSION; IDENTIFICATION;

D O I：

10.1159/000508758

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background:The triple-negative breast cancer (TNBC) constitutes a heterogeneous disease with an aggressive behavior and a poor prognosis. A better understanding of its biology is required to identify new biomarkers and improve clinical outcomes.Summary:To date, the definition and classification of TNBC depends on a multiomic approach including immunohistochemistry (IHC), genomic, and transcriptomic features, and the tumor immune landscape. The development of new technologies has allowed us to sequence the whole cancer genome. The Cancer Genome Atlas (TCGA) and next-generation sequencing have led to a greater knowledge of DNA alterations such as TP53 or BRCA mutations, copy number variations, and DNA methylations. In addition, gene expression profiling has allowed to define a molecular intrinsic classification of TNBC based on mRNA. IHC and genomic profiling are also necessary to identify new immune biomarkers such as the presence of tumor-infiltrating lymphocytes and the expression of immune checkpoint molecules.Key Messages:This review aimed to provide recent knowledge of TNBC biology and classification focused on IHC, transcriptomics, genomic features, and the new immune biomarkers.

引用

页码：208 / 216

页数：9

共 79 条

[1]

Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]

[2] Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].

Adams, Sylvia ;

Gray, Robert J. ;

Demaria, Sandra ;

Goldstein, Lori ;

Perez, Edith A. ;

Shulman, Lawrence N. ;

Martino, Silvana ;

Wang, Molin ;

Jones, Vicky E. ;

Saphner, Thomas J. ;

Wolff, Antonio C. ;

Wood, William C. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Sparano, Joseph A. ;

Badve, Sunil S. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+

[3] Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists [J].

Badve, Sunil ;

Dabbs, David J. ;

Schnitt, Stuart J. ;

Baehner, Frederick L. ;

Decker, Thomas ;

Eusebi, Vincenzo ;

Fox, Stephen B. ;

Ichihara, Shu ;

Jacquemier, Jocelyne ;

Lakhani, Sunil R. ;

Palacios, Jose ;

Rakha, Emad A. ;

Richardson, Andrea L. ;

Schmitt, Fernando C. ;

Tan, Puay-Hoon ;

Tse, Gary M. ;

Weigelt, Britta ;

Ellis, Ian O. ;

Reis-Filho, Jorge S. .

MODERN PATHOLOGY, 2011, 24 (02) :157-167

[4] Sequence analysis of mutations and translocations across breast cancer subtypes [J].

Banerji, Shantanu ;

Cibulskis, Kristian ;

Rangel-Escareno, Claudia ;

Brown, Kristin K. ;

Carter, Scott L. ;

Frederick, Abbie M. ;

Lawrence, Michael S. ;

Sivachenko, Andrey Y. ;

Sougnez, Carrie ;

Zou, Lihua ;

Cortes, Maria L. ;

Fernandez-Lopez, Juan C. ;

Peng, Shouyong ;

Ardlie, Kristin G. ;

Auclair, Daniel ;

Bautista-Pina, Veronica ;

Duke, Fujiko ;

Francis, Joshua ;

Jung, Joonil ;

Maffuz-Aziz, Antonio ;

Onofrio, Robert C. ;

Parkin, Melissa ;

Pho, Nam H. ;

Quintanar-Jurado, Valeria ;

Ramos, Alex H. ;

Rebollar-Vega, Rosa ;

Rodriguez-Cuevas, Sergio ;

Romero-Cordoba, Sandra L. ;

Schumacher, Steven E. ;

Stransky, Nicolas ;

Thompson, Kristin M. ;

Uribe-Figueroa, Laura ;

Baselga, Jose ;

Beroukhim, Rameen ;

Polyak, Kornelia ;

Sgroi, Dennis C. ;

Richardson, Andrea L. ;

Jimenez-Sanchez, Gerardo ;

Lander, Eric S. ;

Gabriel, Stacey B. ;

Garraway, Levi A. ;

Golub, Todd R. ;

Melendez-Zajgla, Jorge ;

Toker, Alex ;

Getz, Gad ;

Hidalgo-Miranda, Alfredo ;

Meyerson, Matthew .

NATURE, 2012, 486 (7403) :405-409

[5] Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis [J].

Bareche, Y. ;

Venet, D. ;

Ignatiadis, M. ;

Aftimos, P. ;

Piccart, M. ;

Rothe, F. ;

Sotiriou, C. .

ANNALS OF ONCOLOGY, 2018, 29 (04) :895-902

[6] Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer [J].

Baselga, J ;

Albanell, J ;

Ruiz, A ;

Lluch, A ;

Gascón, P ;

Guillém, V ;

González, S ;

Sauleda, S ;

Marimón, I ;

Tabernero, JM ;

Koehler, MT ;

Rojo, F .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5323-5333

[7] Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation [J].

Bauer, Joshua A. ;

Chakravarthy, A. Bapsi ;

Rosenbluth, Jennifer M. ;

Mi, Deming ;

Seeley, Erin H. ;

Granja-Ingram, Nara De Matos ;

Olivares, Maria G. ;

Kelley, Mark C. ;

Mayer, Ingrid A. ;

Meszoely, Ingrid M. ;

Means-Powell, Julie A. ;

Johnson, Kimberly N. ;

Tsai, Chiaojung Jillian ;

Ayers, Gregory D. ;

Sanders, Melinda E. ;

Schneider, Robert J. ;

Formenti, Silvia C. ;

Caprioli, Richard M. ;

Pietenpol, Jennifer A. .

CLINICAL CANCER RESEARCH, 2010, 16 (02) :681-690

[8] A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) [J].

Bonnefoi, H. ;

Grellety, T. ;

Tredan, O. ;

Saghatchian, M. ;

Dalenc, F. ;

Mailliez, A. ;

L'Haridon, T. ;

Cottu, P. ;

Abadie-Lacourtoisie, S. ;

You, B. ;

Mousseau, M. ;

Dauba, J. ;

Del Piano, F. ;

Desmoulins, I. ;

Coussy, F. ;

Madranges, N. ;

Grenier, J. ;

Bidard, F. C. ;

Proudhon, C. ;

MacGrogan, G. ;

Orsini, C. ;

Pulido, M. ;

Goncalves, A. .

ANNALS OF ONCOLOGY, 2016, 27 (05) :812-818

[9] Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer [J].

Burstein, Matthew D. ;

Tsimelzon, Anna ;

Poage, Graham M. ;

Coyington, Kyle R. ;

Contreras, Alejandro ;

Fuqua, Suzanne A. W. ;

Sayage, Michelle I. ;

Osborne, C. Kent ;

Hilsenbeck, Susan G. ;

Chang, Jenny C. ;

Mills, Gordon B. ;

Lau, Ching C. ;

Brown, Powel H. .

CLINICAL CANCER RESEARCH, 2015, 21 (07) :1688-1698

[10] TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer [J].

Carey, Lisa A. ;

Rugo, Hope S. ;

Marcom, P. Kelly ;

Mayer, Erica L. ;

Esteva, Francisco J. ;

Ma, Cynthia X. ;

Liu, Minetta C. ;

Storniolo, Anna Maria ;

Rimawi, Mothaffar F. ;

Forero-Torres, Andres ;

Wolff, Antonio C. ;

Hobday, Timothy J. ;

Ivanova, Anastasia ;

Chiu, Wing-Keung ;

Ferraro, Madlyn ;

Burrows, Emily ;

Bernard, Philip S. ;

Hoadley, Katherine A. ;

Perou, Charles M. ;

Winer, Eric P. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2615-2623

← 1 2 3 4 5 6 7 8 →